Protara Therapeutics, Inc. (TARA) NASDAQ

3.14

-0.04(-1.26%)

Updated at July 31 11:02AM

Currency In USD

Protara Therapeutics, Inc.

Address

345 Park Avenue South

New York City, NY 10010

United States of America

Phone

646 844 0337

Sector

Healthcare

Industry

Biotechnology

Employees

28

First IPO Date

October 22, 2014

Key Executives

NameTitlePayYear Born
Mr. Jesse SheffermanCo-founder, Chief Executive Officer, President & Director1.14M1972
Mr. Patrick Fabbio M.B.A.Chief Financial Officer782,4091968
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.Co-Founder & Chief Scientific Operations Officer962,0331981
Dr. Leonardo Viana Nicacio M.D.Chief Medical Officer01978
Ms. Hannah FryVice President, Principal Accounting Officer & Controller01991
Dr. Shane Williams Ph.D.Chief People Officer0N/A
Ms. Justine O'MalleySenior Vice President of Investor Relations & Corporate Affairs0N/A
Ms. Mary J. Grendell J.D.General Counsel & Corporate Secretary0N/A

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.